Biosimilar Antibodies

Tafolecimab (IBI-306) is a human IgG2 monoclonal antibody designed to specifically target and bind to proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9, Tafolecimab effectively inhibits PCSK9-mediated endocytosis of low-density lipoprotein (LDL) receptors, thereby enhancing the clearance of LDL cholesterol (LDL-C) from the bloodstream. This mechanism leads to a significant reduction in LDL-C levels, making Tafolecimab a valuable tool for research into hypercholesterolemia and potential therapeutic interventions.

Recaticimab (SHR-1209) is a humanized monoclonal antibody that is orally active and selectively targets proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9 with high affinity, Recaticimab effectively increases the expression of low-density lipoprotein receptors (LDLR) on hepatocyte surfaces, subsequently leading to a reduction in plasma low-density lipoprotein cholesterol (LDL-C) levels. This antibody is particularly valuable for research focused on hypercholesterolemia and hyperlipidemia, offering a promising tool for investigating the regulation and management of cholesterol levels.

Crusekitug is a humanized monoclonal antibody that selectively targets human interleukin 17A (IL-17A). By specifically binding to IL-17A, Crusekitug impedes its signal transduction pathways, thereby exhibiting immunosuppressive and anti-inflammatory effects. This antibody is particularly valuable for research into autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis, offering insights into disease mechanisms and potential therapeutic interventions.

Vebanvibart is a human monoclonal antibody of the IgG1κ subtype designed to specifically target SARS-CoV-2. For experimental control purposes, the recommended isotype control is Human IgG1 kappa Isotype Control. This specificity and isotype make Vebanvibart suitable for research focused on viral pathogenesis and immune response to SARS-CoV-2.

Alcestobart is a human monoclonal antibody of the IgG4κ subtype that specifically targets LAG3. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as the isotype control. This pairing ensures accurate assessment of target specificity and antibody performance in research applications.

Betifisolimab (MSB-2311) is a humanized monoclonal antibody that targets the immunosuppressive ligand PD-L1. This antibody is designed for investigative use in the study of advanced solid tumors and hematological malignancies, offering a promising tool for research into tumor immunology and potential therapeutic interventions.

Emunkitug is a humanized IgG1κ monoclonal antibody specifically targeting TNFRSF1B. For experimental control purposes, Human IgG1 kappa Isotype Control is recommended.

Letaplimab (IBI-188) is a human IgG4 monoclonal antibody targeting CD47, a protein frequently overexpressed on the surface of cancer cells and acting as a ligand for signal regulatory protein alpha (SIRPα). By binding to CD47, Letaplimab disrupts its interaction with SIRPα, thereby enhancing the phagocytosis of tumor cells. This mechanism positions Letaplimab as a promising therapeutic agent in the field of oncology, particularly for the treatment of cancers characterized by high CD47 expression.

The Anti-Bcl-2 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target B-cell lymphoma 2 (Bcl-2). This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 145.74 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa. This antibody is essential for research focused on apoptosis and cancer biology, particularly in studies investigating the regulation of cell death and survival.

Grisnilimab is an IgG2a monoclonal antibody targeting CD7, implicated in tumor suppression and relevant to the pathogenesis of Wilms' tumor. This antibody functions by regulating the transcription of various target genes and may also play a role in the post-transcriptional processing of RNA. Grisnilimab is designed for research applications focusing on the molecular mechanisms of tumorigenesis and potential therapeutic interventions.

Refanezumab (GSK249320) is a humanized IgG1 monoclonal antibody targeting myelin-associated glycoprotein (MAG). This antibody specifically binds to MAG, thereby inhibiting its role in suppressing axonal regeneration. Demonstrating the ability to traverse the blood-brain barrier in animal models of stroke, Refanezumab offers promising potential for facilitating functional recovery following stroke events. This therapeutic candidate is pivotal for research focused on neural repair and neuroregenerative pathways.

Gumokimab (AK 111) is a monoclonal antibody specifically designed to target IL-17A. This antibody effectively inhibits the interaction between IL-17A and its receptor, IL-17R, through competitive binding. It is primarily utilized in research focused on inflammatory conditions such as psoriasis and ankylosing spondylitis, offering a valuable tool for the investigation of the pathophysiological roles of IL-17A in these diseases.

The Anti-CD59 Antibody is a humanized antibody expressed in Chinese Hamster Ovary (CHO) cells, specifically designed to target CD59. This antibody is comprised of a muIgG1 type heavy chain and a huκ type light chain, with an estimated molecular weight of 150 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for a variety of research applications focusing on the role of CD59 in immune regulation and disease pathogenesis.

Mapatumumab (HGS-ETR1) is a fully human IgG1 monoclonal antibody designed as an agonist for tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). This antibody selectively binds to TRAIL-R1, potentially inducing apoptosis in cells expressing this receptor. Mapatumumab is primarily utilized in oncological research to study its efficacy and mechanism in promoting cancer cell apoptosis.

Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody specifically targeting IL-17A, a cytokine implicated in the pathogenesis of various autoimmune disorders. This antibody is utilized primarily in the investigation of autoimmune diseases including psoriatic arthritis, offering a valuable tool for elucidating disease mechanisms and potential therapeutic pathways.

Gacovetug is a chimeric antibody designed as a dimer type, specifically targeting the FaeG adhesin of F4+ enterotoxigenic Escherichia coli (ETEC). It features a variable heavy chain-human constant region (VH-h-CH2-CH3-CHS) architecture, making it highly specific for its bacterial target. This antibody is pivotal for research focused on the pathogenesis and immune response to ETEC infections, providing a valuable tool for the development of therapeutic strategies and diagnostic applications.

The Anti-MPL / TPOR / CD110 (TA136) antibody specifically binds to the tertiary structure of MPL, also known as thrombopoietin receptor or CD110. This monoclonal antibody recognizes MPL with high specificity, making it a valuable tool in the study of MPL's role in signaling pathways that regulate platelet production. Its potential therapeutic applications include the treatment of congenital amegakaryocytic thrombocytopenia, a disorder characterized by platelet deficiency. This antibody is suitable for a range of experimental applications, including flow cytometry, Western blotting, and immunohistochemistry.

Inotuzumab is a humanized recombinant antibody of the IgG4, κ isotype, specifically designed to target human CD22. This antibody can be conjugated with the cytotoxic agent ozogamicin, forming an antibody-drug conjugate (ADC) utilized in research focused on acute lymphoblastic leukemia and non-Hodgkin lymphoma. Inotuzumab's precise targeting mechanism facilitates the delivery of therapeutic agents directly to malignant cells, thereby enhancing the efficacy and specificity of treatment modalities under investigation.

Posdinemab is a humanized IgG1κ monoclonal antibody designed to specifically target the microtubule-associated protein tau (MAPT). This antibody is engineered for high specificity and affinity in recognizing and binding to the tau protein, which is implicated in neurodegenerative disorders such as Alzheimer's disease. Posdinemab is utilized in research focused on the pathology and therapeutic interventions of tau-related diseases.

Suptavumab (REGN2222) is a human monoclonal antibody designed to specifically bind to and inhibit a conserved epitope on both the A and B subtypes of Respiratory Syncytial Virus (RSV). This antibody is utilized primarily in the investigation of RSV infections, providing a valuable tool for researchers studying the virus's pathogenesis and potential therapeutic interventions.

Actoxumab is a recombinant monoclonal antibody specifically designed to neutralize Clostridium difficile toxin A (TcdA). By binding to TcdA, Actoxumab effectively prevents the toxin's deleterious effects on the intestinal wall and mitigates the associated inflammatory responses. This antibody is particularly noted for its synergistic action when used in conjunction with Bezlotoxumab, which targets Clostridium difficile toxin B (TcdB). Together, these antibodies provide a comprehensive approach to managing the effects of both major C. difficile toxins. Actoxumab is valuable in research focused on the pathogenesis and treatment of C. difficile infections.

STI-6643 is a fully human IgG4 monoclonal antibody specifically targeting CD47. It demonstrates significant anti-tumor efficacy while exhibiting minimal toxicity to red blood cells and lymphocytes. For isotype control, Human IgG4 (S228P) kappa, Isotype Control is recommended. This specificity and safety profile make STI-6643 a valuable tool for research in cancer immunotherapy.

Dinutuximab (Unituxin; APN-311) is a chimeric monoclonal antibody derived from both human and murine sources, specifically targeting GD2. This antibody has demonstrated significant efficacy in prolonging event-free and overall survival in patients with high-risk neuroblastoma. It is used in a therapeutic regimen that includes granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (interleukin-2 [IL-2]), and isotretinoin (13-cis-retinoic acid [RA]), enhancing its effectiveness in clinical applications.

Sirexatamab is a biologically active peptide designed for use in a variety of biochemical studies. This peptide specifically targets and binds to its corresponding receptor, making it an ideal candidate for research focused on receptor-ligand interactions, signaling pathways, and cellular responses. Sirexatamab's high specificity and efficacy are essential for researchers studying these critical aspects of cell biology and molecular medicine.

Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody designed to selectively bind to the programmed death-1 (PD-1) receptor with a dissociation constant (KD) of 74 pM. By inhibiting the interaction between PD-1 and its ligands PD-L1 and PD-L2, Sintilimab effectively restores the body's endogenous antitumor T-cell response. Research indicates that when combined with prebiotics, Sintilimab effectively reduces tumor volume and modulates the balance of immune cell subpopulations in mouse models of lung adenocarcinoma. This antibody is primarily used in the investigation of classical Hodgkin's lymphoma, non-small cell lung cancer, and esophageal cancer, making it a valuable tool for oncological research and therapeutic explorations.

Ponezumab (PF-04360365) is a humanized IgG2 monoclonal antibody designed to target and reduce amyloid beta (Aβ) levels in the central nervous system. Demonstrating efficacy in preclinical studies, Ponezumab has shown to enhance cognitive performance in mouse models across various learning and memory paradigms. This antibody is particularly valuable for research focused on the pathophysiology and potential treatments for Alzheimer's disease.

Ocrelizumab (Ocrevus) is a humanized monoclonal antibody targeting CD20, designed to deplete B cells. It operates primarily through antibody-dependent cellular cytotoxicity (ADCC), effectively inhibiting lesion formation in multiple sclerosis models in mice. This mechanism underscores its potential for application in research focused on autoimmune diseases and immunotherapy.

The Anti-TM4SF1 Antibody is a human monoclonal antibody produced in Chinese hamster ovary (CHO) cells, specifically designed to target the TM4SF1 protein. This antibody features a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For isotype control, researchers should use the Human IgG1 kappa, Isotype Control, ensuring accurate and reliable experimental comparisons. This product is essential for studies focused on the biological functions and pathological roles of TM4SF1 in cellular processes.

Tuvonralimab (PSB-205; QL1706) is a dual-action immunotherapy agent comprising a combination of Iparomlimab, an anti-PD-1 IgG4 antibody, and Tuvonralimab, an anti-CTLA-4 IgG1 antibody. This formulation is designed to synergistically inhibit both the PD-1 and CTLA-4 immune checkpoints, enhancing antitumor immune responses. Tuvonralimab is utilized primarily in research focused on cancer immunotherapy, aiming to study and potentially enhance the efficacy of checkpoint blockade strategies.

Zubotamig is a chimeric human antibody of the IgG1κ subtype that specifically targets CD3E and VTCN1. This monoclonal antibody is engineered for precise binding affinity to these antigens, making it an invaluable tool for research into T-cell activation and immune regulation. Suitable for a variety of immunological assays, Zubotamig facilitates advanced studies in immunotherapy and autoimmune disease mechanisms.

Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antibody that functions as an antagonist by selectively targeting and binding to LILRB2. This interaction inhibits LILRB2 from associating with its natural ligands, including both classical and non-classical MHC class I molecules. By preventing LILRB2 from binding to HLA-A/B and HLA-G, which are markers of immunotolerance on tumor cells, Polzastobart effectively disrupts this inhibitory signal and enhances the production of pro-inflammatory cytokines in macrophages. This mechanism classifies Polzastobart as a macrophage immune checkpoint inhibitor, making it a critical tool in cancer immunotherapy research.

Tabituximab (OTSA101) is a humanized monoclonal antibody designed to specifically target the frizzled class receptor 10 (FZD10). This antibody binds with high specificity to FZD10, a receptor implicated in several oncogenic processes, making it a critical component in cancer research and therapeutic development.

Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody engineered to specifically target and bind to the programmed death-ligand 1 (PD-L1). This antibody selectively inhibits the interaction between PD-L1 and its receptor, programmed death-1 (PD-1), a critical pathway exploited by tumors to evade immune detection. Through this mechanism, Garivulimab exhibits potent antitumor activity, making it a valuable tool for cancer immunotherapy research.

Murlentamab (3C23K; GM102) is a humanized monoclonal antibody targeting AMHRII, the anti-Müllerian hormone receptor II. This antibody plays a crucial role in enhancing macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC), a key mechanism in immune defense against tumors. Murlentamab facilitates the creation of a pro-inflammatory and anti-tumor microenvironment, effectively recruiting and activating T cells. Additionally, it inhibits tumor growth by directing the differentiation of naïve macrophages and reprogramming tumor-associated macrophages (TAMs) towards phenotypes that support tumor eradication. This makes Murlentamab a valuable tool for research in cancer immunotherapy and macrophage biology.

Tamgiblimab (IBI939) is a fully human monoclonal antibody that specifically targets the T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). This antibody exhibits potent anticancer properties by modulating immune system responses, potentially enhancing the recognition and destruction of cancer cells. Tamgiblimab is designed for therapeutic applications in oncology, focusing on harnessing the body's immune system to combat various malignancies.

Ispectamab is a human IgG1 κ monoclonal antibody specifically targeting TNFRSF17. For optimal experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

The Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13) is a chimeric mouse IgG1 monoclonal antibody designed to specifically target human LFA-1α/CD11a. For accurate isotype control in experimental procedures, it is recommended to use Mouse IgG1 kappa, Isotype Control. This antibody serves as a critical tool for the study of immune cell activation and adhesion in various immunological research settings.

Dacetuzumab (SGN-40) is a humanized IgG1 monoclonal antibody targeting CD40, demonstrating potent anti-lymphoma properties. This therapeutic antibody exerts its effects through immune effector functions, including antibody-dependent cellular cytotoxicity and phagocytosis (ADCC/ADCP), leading to the effective elimination of tumor cells. Dacetuzumab is primarily utilized in research focused on multiple myeloma, offering significant insights into disease mechanisms and potential therapeutic strategies.

Efalizumab is a humanized monoclonal antibody that selectively targets CD11a, the α subunit of lymphocyte function-associated antigen 1 (LFA-1). By modulating T cell activity, Efalizumab effectively inhibits T cell activation, adhesion to keratinocytes, and trafficking to cutaneous sites. This antibody is particularly valuable for research into the pathophysiology and potential treatments of plaque psoriasis, offering insights into T cell-mediated skin disorders.

Zeluvalimab (AMG-404) is a monoclonal antibody specifically designed to target the PD-1 receptor. This antibody is utilized primarily in the research of various cancer types, facilitating studies focused on immune checkpoint inhibition and tumor immune evasion mechanisms. Zeluvalimab serves as a critical tool in oncology research, offering potential insights into the modulation of immune responses against tumor cells.

Mitazalimab (ADC-1013; JNJ-64457107) functions as an FcγR-dependent CD40 agonist, specifically designed to exhibit tumor-directed activity. This therapeutic agent effectively activates antigen-presenting cells, such as dendritic cells (DCs), thereby initiating the activation of tumor-reactive T cells. Consequently, Mitazalimab promotes the infiltration and activation of tumor-specific T cells, which are instrumental in targeting and destroying tumor cells. Additionally, this compound plays a crucial role in remodeling the tumor-infiltrating myeloid microenvironment, enhancing its therapeutic efficacy against cancerous tissues.

Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody that specifically targets activin receptor-like kinase 1 (ALK-1). Demonstrating a high binding affinity, Ascrinvacumab interacts with human ALK1 with a dissociation constant (Kd) of 7 nM. This antibody is primarily utilized in scientific studies focused on the pathogenesis and therapeutic interventions of hepatocellular carcinoma (HCC).

Cinpanemab (BIIB054) is a human-derived monoclonal antibody specifically designed to target α-synuclein. This antibody has significant applications in the research of Parkinson's disease, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions targeting α-synuclein aggregation.

The Anti-CD44 Antibody (Hermes-1) is a chimeric rat IgG2a, κ antibody designed to specifically target human CD44. This product is ideal for research focused on the cell-surface glycoprotein CD44, which is involved in cell-cell interactions, cell adhesion, and migration. For accurate experimental control, it is recommended to use the Rat IgG2a kappa Isotype Control.

Anti-TSHR Antibody (M22) is a humanized IgG1 kappa monoclonal antibody designed to specifically target the thyrotropin receptor (TSHR). This antibody effectively inhibits the interaction between thyroid-stimulating hormone (TSH) and its receptor, TSHR, thereby modulating receptor activity. For accurate experimental control, it is recommended to use Human IgG1 kappa Isotype Control. This product is ideal for research applications focusing on thyroid function and autoimmune thyroid disorders.

Perenostobart is a humanized monoclonal antibody of the immunoglobulin G4-kappa subclass, specifically targeting ENTPD1/CD39. This antibody functions as an immunostimulant and possesses antineoplastic properties, making it a valuable tool in cancer immunotherapy research. Its selective binding to ENTPD1/CD39, an enzyme involved in the hydrolysis of extracellular nucleotides, modulates immune responses and potentially disrupts tumor-promoting mechanisms. Perenostobart is applicable in studies focused on the regulation of immune checkpoints and the tumor microenvironment.

Clazakizumab is a monoclonal antibody designed to target and neutralize interleukin-6 (IL-6), a cytokine implicated in a wide array of inflammatory responses. This antibody exhibits high affinity and specificity for IL-6, making it a valuable tool in the study of cytokine-mediated processes. Clazakizumab has potential applications in the inhibition of the cytokine storm associated with SARS-CoV-2 infection in COVID-19 patients. Additionally, it is utilized in research focused on psoriatic arthritis (PsA) and renal antibody-mediated rejection, providing insights into the therapeutic mechanisms and potential clinical applications in these conditions.

The Anti-SLC40A1 Antibody is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the SLC40A1 protein, with a predicted molecular weight of 150 kDa. This antibody is designed for the precise detection and study of SLC40A1, a key transporter involved in iron homeostasis and related biological processes.

Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody engineered in Chinese Hamster Ovary (CHO) cells with a targeted knockout of the fucosyltransferase 8 gene (FUT8). This genetic modification results in a fucose-deficient antibody, significantly enhancing its antibody-dependent cellular cytotoxicity (ADCC) capabilities. Specifically designed to target CD19, Inebilizumab demonstrates increased efficacy in mediating ADCC against B cells. This product is ideal for advanced research applications focusing on immune-mediated diseases such as multiple sclerosis and neuromyelitis optica, providing a valuable tool for studies into the pathogenesis and treatment of these conditions.